ArticleFrontiers in oncology2025
Global burden of colorectal cancer attributable to high fasting plasma glucose from 1990 to 2021 and projection to 2040.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High fasting plasma glucose (HFPG) is an established risk factor for colorectal cancer (CRC). This study analyzes global epidemiological patterns and temporal trends of HFPG-attributable CRC burden from 1990 to 2021, with projections to 2040. Methods: Using Global Burden of Disease 2021 data, we assessed geographical, sex-specific, age-related, and socio-demographic index (SDI) variations in mortality and disability-adjusted life years (DALYs). Joinpoint regression analysis was employed to evaluate the trends and inflection points, and the Bayesian Age-Period-Cohort (BAPC) model was performed to project future burden. Results: In 2021, HFPG accounted for 82,421 CRC deaths (95% UI: 42,427-125,402) and 1,750,923 DALYs (95% UI: 900,573-2,657,995) globally - marking substantial increases since 1990. Age-standardized mortality rates (ASMR) and DALY rates (ASDR) showed modest increases during 1990-2021 with an AAPCs of 0.31, but significant decline were identified post-2019, particularly in ASMR (APC = -0.94, Conclusion: Despite global increases in HFPG-attributable CRC burden since 1990, recent declining trends (2019 onward) suggest potential progress in burden mitigation. Considering COVID-19 pandemic impacts on healthcare systems, post-2019 trends require cautious interpretation. Further longitudinal studies are essential to validate these trends. Given the significant variations across gender, age, and SDI, targeted interventional strategies should be developed and implemented to effectively manage this disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.